Scholarlink

<p>Osteoporosis and chronic bone pain (CBP) are prevalent complications in thalassemia, significantly affecting their quality of life. This study aimed to evaluate the efficacy of Denosumab in improving bone mineral density (BMD) and reducing CBP in thalassemic patients with osteoporosis. Single-arm interventional study. Twenty-three thalassemic patients with osteoporosis were enrolled. Dual-energy X-ray absorptiometry (DEXA) was performed at baseline and after two doses of Denosumab to assess T-scores/Z-scores and BMD at the lumbar spine (L1–L4) and left hip. Twelve patients received two additional doses and underwent repeat DEXA scans. Fracture history was recorded. CBP was evaluated using the Huskisson Visual Analog Scale (VAS) before treatment and after two and four doses for 23 and 12 patients, respectively. Statistical analysis was performed using the Wilcoxon signed-rank test, with <i>p</i> &lt; 0.05 considered significant. Baseline median T-scores/Z-scores were−3.2 (L1–L4) and−2.6 (hip). After two doses, scores improved to−2.5 and−2.2, respectively (<i>p</i> &lt; 0.001) with significant improvement in BMD. In 12 patients receiving four doses, scores improved further to−1.75 (L1–L4) and−2.0 (hip) from a median of−3.45 and−2.8 respectively with significant p-value. Among 14 patients reporting CBP, VAS scores declined from a median of 5.0&#xa0;cm at baseline to 2.5&#xa0;cm after two doses (<i>p</i> = 0.001). It further reduced to 2&#xa0;cm after four doses in a subset of 12 patients (<i>p</i> = 0.017). Denosumab significantly improved BMD and reduced CBP in thalassemic patients with osteoporosis. These findings support its role as a promising therapeutic option in this population.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Improving Bone Density and Alleviating Pain with Denosumab in Thalassemia Patients with Osteoporosis: Evidence from an Interventional Study

  • 期刊论文

  • 发表日期：

    2026年3月11日

查看全文
  • Sneha Bhosle,
  • Swetlana Mukherjee,
  • Maddukuri Sriram,
  • Amita Mahajan

摘要

Osteoporosis and chronic bone pain (CBP) are prevalent complications in thalassemia, significantly affecting their quality of life. This study aimed to evaluate the efficacy of Denosumab in improving bone mineral density (BMD) and reducing CBP in thalassemic patients with osteoporosis. Single-arm interventional study. Twenty-three thalassemic patients with osteoporosis were enrolled. Dual-energy X-ray absorptiometry (DEXA) was performed at baseline and after two doses of Denosumab to assess T-scores/Z-scores and BMD at the lumbar spine (L1–L4) and left hip. Twelve patients received two additional doses and underwent repeat DEXA scans. Fracture history was recorded. CBP was evaluated using the Huskisson Visual Analog Scale (VAS) before treatment and after two and four doses for 23 and 12 patients, respectively. Statistical analysis was performed using the Wilcoxon signed-rank test, with p < 0.05 considered significant. Baseline median T-scores/Z-scores were−3.2 (L1–L4) and−2.6 (hip). After two doses, scores improved to−2.5 and−2.2, respectively (p < 0.001) with significant improvement in BMD. In 12 patients receiving four doses, scores improved further to−1.75 (L1–L4) and−2.0 (hip) from a median of−3.45 and−2.8 respectively with significant p-value. Among 14 patients reporting CBP, VAS scores declined from a median of 5.0 cm at baseline to 2.5 cm after two doses (p = 0.001). It further reduced to 2 cm after four doses in a subset of 12 patients (p = 0.017). Denosumab significantly improved BMD and reduced CBP in thalassemic patients with osteoporosis. These findings support its role as a promising therapeutic option in this population.